# Chronic Disease Management Scenarios

## Scenario 1: Type 2 Diabetes Mellitus Management

### Patient Profile
- **Name:** Maria Santos
- **Age:** 56 years
- **Gender:** Female
- **Weight:** 165 lbs (75 kg)
- **Height:** 5'4" (163 cm)
- **BMI:** 27.8
- **Occupation:** Office manager

### Medical History
- **Primary:** Type 2 Diabetes Mellitus (8 years)
- **Medical History:**
  - Hypertension (6 years)
  - Dyslipidemia (5 years)
  - Obesity (10 years)
- **Family History:** Mother (diabetes, hypertension), Father (diabetes, heart attack)
- **Medications:** 
  - Metformin 1000mg BID
  - Glipizide 5mg daily
  - Lisinopril 20mg daily
  - Atorvastatin 40mg daily

### Chief Complaint
"My blood sugars have been running higher lately, and I feel more tired than usual. I'm also having some vision changes."

### Current Symptoms
- **Fatigue:** Increasing over past 3 months
- **Polyuria/Polydipsia:** Mild increase
- **Vision Changes:** Blurred vision, especially reading
- **Weight:** Stable (no significant change)
- **Infection History:** Recent UTI (2 months ago)

### Vital Signs
- **BP:** 145/88 mmHg
- **HR:** 78 bpm
- **Weight:** 165 lbs (baseline)
- **BMI:** 27.8

### Laboratory Results
- **HbA1c:** 8.7% (goal <7%)
- **Fasting Glucose:** 175 mg/dL (goal 80-130 mg/dL)
- **Random Glucose:** 210 mg/dL
- **CMP:**
  - Creatinine: 1.1 mg/dL
  - eGFR: 55 mL/min/1.73m² (CKD stage 3a)
  - Potassium: 4.2 mEq/L
- **Lipid Panel:**
  - Total cholesterol: 180 mg/dL
  - LDL: 95 mg/dL
  - HDL: 42 mg/dL
  - Triglycerides: 215 mg/dL

### Additional Testing
- **Urinalysis:** Microalbuminuria positive (100 mg/g creatinine)
- **Comprehensive Diabetic Eye Exam:** Non-proliferative diabetic retinopathy
- **Foot Exam:** Decreased sensation, normal pulses

### Clinical Decision Points

#### Current Management Assessment
1. **Glycemic Control:** Poor control (HbA1c 8.7%)
2. **Diabetes Duration:** 8 years (increased complication risk)
3. **Complications Present:**
   - **Microalbuminuria** (early nephropathy)
   - **Retinopathy** (mild, non-proliferative)
   - **Neuropathy** (sensory)

#### ADA Standards of Care (2024)
- **HbA1c Goal:** <7% (individualized based on complications)
- **BP Goal:** <140/90 mmHg (diabetic patients)
- **LDL Goal:** <100 mg/dL (high risk)
- **BMI Goal:** <25 or 5-10% weight loss

### Treatment Plan

#### Medication Optimization
1. **Insulin Therapy Initiation:**
   - **Basal insulin:** Glargine 20 units at bedtime
   - **Titration:** Increase by 2 units every 3 days
   - **Target fasting glucose:** 80-130 mg/dL

2. **Oral Medication Review:**
   - **Continue metformin** (kidney function adequate)
   - **Discontinue glipizide** (increase hypoglycemia risk with insulin)
   - **Consider SGLT-2 inhibitor** (cardiovascular benefits)

#### Lifestyle Modifications
1. **Dietary counseling:**
   - **Carbohydrate counting**
   - **Portion control**
   - **ADA meal planning**

2. **Exercise prescription:**
   - **150 minutes/week** moderate aerobic activity
   - **Resistance training** 2-3 times/week
   - **Start low:** 10-15 minutes if sedentary

3. **Weight loss goals:**
   - **Target:** 5-10% weight loss (8-16 lbs)
   - **Behavioral counseling**
   - **Support groups**

#### Complication Management
1. **Diabetic Retinopathy:**
   - **Ophthalmology referral** (already established)
   - **Close monitoring** every 6 months
   - **Optimize glycemic control**

2. **Diabetic Nephropathy:**
   - **ACE inhibitor** (continued lisinopril)
   - **Blood pressure control** <130/80 mmHg
   - **Monitor eGFR** every 3 months
   - **Dietary protein restriction** if progressive

3. **Diabetic Neuropathy:**
   - **Gabapentin** for symptomatic relief
   - **Foot care education**
   - **Proper footwear**
   - **Daily foot inspection**

### Monitoring Schedule

#### Initial Intensive Monitoring (First 3 months)
1. **Glucose Monitoring:**
   - **Fasting glucose:** Daily
   - **Post-meal glucose:** 2 hours after largest meal
   - **Continuous glucose monitor** consideration

2. **Laboratory Follow-up:**
   - **HbA1c:** Every 3 months until target achieved
   - **Comprehensive metabolic panel:** Monthly
   - **Lipid panel:** Every 6 months

3. **Clinic Visits:**
   - **Monthly visits** initially
   - **Nurse educator** visits
   - **Dietitian referral**

#### Long-term Monitoring (After target achieved)
1. **Quarterly HbA1c**
2. **Annual comprehensive evaluation:**
   - **Eye exam**
   - **Foot exam**
   - **Microalbumin screening**
   - **Lipid panel**
   - **Comprehensive metabolic panel**

### Expected Outcomes
- **HbA1c target:** <7% (or <6.5% if achievable safely)
- **Blood pressure:** <140/90 mmHg
- **Weight loss:** 5-10% body weight
- **Quality of life:** Improved energy and vision

### Learning Objectives
- Apply ADA Standards of Care
- Initiate and titrate insulin therapy
- Screen for diabetes complications
- Coordinate multidisciplinary diabetes care
- Implement lifestyle modifications

---

## Scenario 2: Hypertension Management

### Patient Profile
- **Name:** Robert Thompson
- **Age:** 48 years
- **Gender:** Male
- **Weight:** 205 lbs (93 kg)
- **Height:** 5'9" (175 cm)
- **BMI:** 30.4
- **Occupation:** Sales manager

### Medical History
- **Primary:** Hypertension (newly diagnosed)
- **Medical History:**
  - Obesity (15 years)
  - Sleep apnea (undiagnosed)
  - Hyperlipidemia (3 years)
- **Family History:** Father (hypertension, stroke at 58), Mother (hypertension)
- **Social History:** Smoker (15 cigarettes/day, 20 years), Social alcohol use
- **Medications:** Atorvastatin 20mg daily

### Chief Complaint
"I've been feeling headaches lately and my doctor found my blood pressure is high during my annual physical."

### Presentation Timeline
- **3 months ago:** Annual physical with elevated BP readings
- **1 month ago:** 24-hour ambulatory BP monitoring confirmed diagnosis
- **2 weeks ago:** Lifestyle counseling initiated
- **Today:** Follow-up visit for treatment decisions

### Vital Signs
- **BP:** 162/98 mmHg (clinic reading)
- **HR:** 84 bpm
- **Weight:** 205 lbs (no change)
- **BMI:** 30.4

### Physical Examination
- **General:** Appears healthy, overweight
- **Cardiovascular:** Regular rhythm, no murmurs
- **Respiratory:** Clear to auscultation
- **Fundoscopy:** Early arteriolar narrowing
- **Extremities:** Normal pulses, no edema

### Ambulatory Blood Pressure Monitoring Results
- **Average Daytime BP:** 158/96 mmHg
- **Average Nighttime BP:** 145/90 mmHg
- **Day-Night Dipping:** 8% (normal 10-20%)
- **Blood Pressure Load:** 95% (goal <25%)

### Laboratory Results
- **CMP:**
  - Creatinine: 1.0 mg/dL
  - eGFR: >60 mL/min/1.73m²
  - Potassium: 4.0 mEq/L
  - Glucose: 95 mg/dL
- **Lipid Panel:**
  - Total cholesterol: 220 mg/dL
  - LDL: 140 mg/dL
  - HDL: 35 mg/dL (low)
  - Triglycerides: 280 mg/dL
- **Urinalysis:** Normal, no protein
- **TSH:** Normal

### Additional Testing
- **Sleep Study:** Moderate obstructive sleep apnea (AHI 18 events/hour)
- **ECG:** Left ventricular hypertrophy (LVH)

### Clinical Decision Points

#### Hypertension Classification (ACC/AHA 2023)
- **Stage 2 Hypertension:** 
  - Systolic ≥140 OR Diastolic ≥90 mmHg
  - Multiple risk factors present

#### Cardiovascular Risk Assessment
1. **High-Risk Features:**
   - **Smoking:** Current smoker
   - **Obesity:** BMI >30
   - **Dyslipidemia:** Elevated LDL
   - **Sleep apnea:** Moderate OSA
   - **LVH:** On ECG

2. **10-Year ASCVD Risk:**
   - **Calculate using Pooled Cohort Equations**
   - Estimated risk: 12.5% (high risk)

### Treatment Plan

#### Initial Medication Therapy
1. **First-Line Combination:**
   - **ACE Inhibitor:** Lisinopril 10mg daily
   - **Thiazide Diuretic:** HCTZ 12.5mg daily
   - **Rationale:** Combination therapy for Stage 2 HTN

2. **Alternative Options:**
   - **ACE/ARB + CCB** (amlodipine)
   - **ACE/ARB + thiazide** (if ccB intolerant)

#### Lifestyle Modifications (DASH Diet + Exercise)
1. **Dietary Changes:**
   - **DASH diet implementation**
   - **Sodium restriction:** <2,300mg/day (goal 1,500mg)
   - **Potassium-rich foods:** Fruits/vegetables
   - **Limit alcohol:** ≤2 drinks/day (men)

2. **Physical Activity:**
   - **150 minutes/week** moderate aerobic exercise
   - **Resistance training:** 2-3 times/week
   - **Weight loss target:** 5-10% body weight

3. **Sleep Apnea Treatment:**
   - **CPAP therapy** initiation
   - **Weight management** (weight loss may improve OSA)

4. **Smoking Cessation:**
   - **Varenicline** 0.5mg BID
   - **Behavioral counseling**
   - **Nicotine replacement therapy**

### Medication Titration Schedule
1. **Month 1:**
   - Current dose: Lisinopril 10mg + HCTZ 12.5mg
   - Target BP: <140/90 mmHg

2. **Month 2-3:**
   - If BP >140/90: Increase doses
   - Lisinopril 20mg + HCTZ 25mg

3. **Month 4-6:**
   - Add third agent if needed
   - Amlodipine 5mg daily
   - Target BP: <130/80 mmHg

### Monitoring Protocol

#### Follow-up Schedule
1. **Monthly visits** until BP controlled
2. **Home BP monitoring:** Daily readings
3. **Laboratory monitoring:**
   - **Basic metabolic panel:** Every 3 months
   - **Lipid panel:** Every 6 months
   - **HbA1c:** Annually

#### Target Blood Pressure Goals
- **General population:** <140/90 mmHg
- **High-risk patients:** <130/80 mmHg
- **Diabetes/CKD:** <130/80 mmHg

### Expected Outcomes
- **BP target achievement:** Within 3-6 months
- **Weight loss:** 10-20 lbs
- **Smoking cessation:** Complete within 1 year
- **ASCVD risk reduction:** 20-30% improvement

### Learning Objectives
- Classify hypertension stages
- Calculate cardiovascular risk
- Apply evidence-based treatment guidelines
- Integrate lifestyle modifications
- Manage treatment-resistant hypertension

---

## Scenario 3: Chronic Obstructive Pulmonary Disease (COPD)

### Patient Profile
- **Name:** Margaret Johnson
- **Age:** 68 years
- **Gender:** Female
- **Weight:** 125 lbs (57 kg)
- **Height:** 5'4" (163 cm)
- **BMI:** 21.5
- **Occupation:** Retired teacher

### Medical History
- **Primary:** COPD, GOLD Stage 3 (severe)
- **Smoking History:** 45 pack-year history (quit 10 years ago)
- **Medical History:**
  - Chronic bronchitis (15 years)
  - Osteoporosis (5 years)
  - Anxiety disorder
- **Medications:** 
  - Tiotropium 18mcg daily
  - Albuterol inhaler PRN
  - Prednisone 10mg daily
  - Sertraline 50mg daily

### Chief Complaint
"I get out of breath just walking to the kitchen, and I've been coughing more than usual with yellow mucus."

### Symptom Assessment
- **Dyspnea:** mMRC Grade 3 (walks slower than people of same age)
- **Cough:** Daily productive cough (15 years)
- **Sputum:** Yellow, thick, ~50mL/day
- **Exacerbations:** 3 in past year (requiring steroids/antibiotics)
- **Activity limitation:** Severe (can't climb stairs)

### Current Exacerbation
- **Onset:** 3 days ago
- **Symptoms:** Increased dyspnea, cough, sputum production
- **Triggers:** Upper respiratory infection
- **Home management:** Increased albuterol use

### Vital Signs
- **BP:** 125/75 mmHg
- **HR:** 95 bpm
- **RR:** 24 breaths/min
- **Temp:** 99.8°F (37.7°C)
- **SpO2:** 88% on room air

### Physical Examination
- **General:** Thin, barrel-chested, pursed-lip breathing
- **Respiratory:** Use of accessory muscles, decreased breath sounds
- **Cardiovascular:** Tachycardic, regular rhythm
- **Extremities:** Digital clubbing, cyanosis

### Pulmonary Function Tests
- **FEV1:** 38% predicted (pre-bronchodilator)
- **FEV1/FVC ratio:** 0.48 (markedly reduced)
- **Post-bronchodilator FEV1:** 40% predicted (minimal improvement)

### Laboratory Results
- **ABG:**
  - pH: 7.38
  - PaCO2: 48 mmHg (elevated)
  - PaO2: 58 mmHg (hypoxemic)
  - HCO3: 28 mEq/L (compensated)
- **Complete Blood Count:** Normal
- **Chest X-ray:** Hyperinflation, flattened diaphragms

### GOLD Classification and Staging
- **COPD Severity:** GOLD Stage 3 (severe)
  - FEV1 30-49% predicted
  - High symptom burden
  - High exacerbation risk

- **mMRC Dyspnea Scale:** Grade 3
- **CAT Score:** 22 (high symptom burden)

### Current Exacerbation Management

#### Immediate Treatment
1. **Bronchodilators:**
   - **Short-acting beta-agonist:** Albuterol nebulizer q4h
   - **Short-acting anticholinergic:** Ipratropium nebulizer q4h
   - **Combination therapy:** Standard

2. **Systemic Corticosteroids:**
   - **Prednisone:** 40mg daily × 5 days
   - **Tapering:** Not routinely recommended
   - **Duration:** Consider 5-14 days

3. **Antibiotics (if indicated):**
   - **Purulent sputum:** ✓ (yellow sputum)
   - **Increased dyspnea:** ✓
   - **Increased sputum volume:** ✓
   - **Azithromycin 500mg × 3 days**

4. **Oxygen Therapy:**
   - **Target SpO2:** 88-92% (chronic CO2 retention)
   - **Start at:** 1-2L/min via nasal cannula

### Clinical Decision Points

#### Exacerbation Severity Assessment
1. **Moderate Exacerbation:**
   - Increased dyspnea and sputum
   - No signs of respiratory failure
   - Managed as outpatient

2. **Treatment Response:**
   - **Home management:** Appropriate initially
   - **Emergency visit:** Worsening symptoms
   - **Hospitalization criteria:** Hypoxemia, hypercapnia

#### Long-term Management Strategy
1. **ICS/LABA Combination:**
   - **Fluticasone-salmeterol 45/21mcg** 2 puffs BID
   - **Triple therapy consideration**
   - **ESW 2023:** Add ICS if eosinophils >300

2. **Pulmonary Rehabilitation:**
   - **6-8 week program**
   - **Exercise training + education**
   - **Referral for enrollment**

### Hospital Admission Considerations
1. **Arterial Blood Gas:**
   - **PaO2 <60 mmHg** or **PaCO2 >45 mmHg:** Admission
   - **Current:** PaO2 58, PaCO2 48 → Consider admission

2. **Clinical Decision:**
   - **Outpatient management** initially
   - **Close monitoring** with home health
   - **Return instructions** if worsening

### Long-term Management Plan

#### Maintenance Medications
1. **Triple Therapy (ICS/LABA/LAMA):**
   - **Current:** Tiotropium (LAMA) only
   - **Add:** ICS/LABA combination
   - **Rationale:** Severe COPD, frequent exacerbations

2. **PDE4 Inhibitor:**
   - **Roflumilast 500mcg daily**
   - **Consider if:** Chronic bronchitis phenotype

3. **Home Oxygen:**
   - **Indication:** PaO2 <55 mmHg or SaO2 <88%
   - **Continuous:** 15 hours/day minimum
   - **Assessment:** When stable

#### Non-pharmacological Interventions
1. **Smoking Cessation:** Maintained (10 years)
2. **Pulmonary Rehabilitation:** Refer immediately
3. **Vaccinations:**
   - **Influenza:** Annual
   - **Pneumococcal:** PCV20 or PPSV23
   - **COVID-19:** Updated boosters

4. **Nutrition:**
   - **BMI monitoring** (current: 21.5)
   - **Protein supplementation**
   - **Small frequent meals**

### Monitoring and Follow-up
1. **Stable COPD (3-4 months):**
   - Symptom assessment (CAT score)
   - Spirometry (FEV1 change)
   - Exacerbation history
   - Medication adherence

2. **Follow-up Schedule:**
   - **Clinic visits:** Every 3-6 months
   - **Home monitoring:** SpO2, symptoms
   - **Emergency action plan:** Written instructions

### Expected Outcomes
- **Exacerbation reduction:** 50% with optimal therapy
- **Improved quality of life:** CAT score reduction
- **Slowed FEV1 decline:** Optimal bronchodilation
- **Exercise tolerance:** Pulmonary rehabilitation benefits

### Learning Objectives
- Classify COPD severity using GOLD criteria
- Manage acute COPD exacerbations
- Implement appropriate maintenance therapy
- Recognize indications for oxygen therapy
- Coordinate multidisciplinary COPD care

---

## Additional Chronic Disease Scenarios

### Heart Failure with Reduced Ejection Fraction
- **Patient:** 65-year-old male with NYHA Class III symptoms
- **Key points:** GDMT optimization, device therapy consideration
- **Learning objectives:** Heart failure management principles

### Chronic Kidney Disease
- **Patient:** 58-year-old diabetic with CKD Stage 4
- **Key points:** ACE/ARB therapy, protein restriction, anemia management
- **Learning objectives:** CKD progression prevention

### Obesity Management
- **Patient:** 35-year-old with BMI 35 and metabolic syndrome
- **Key points:** Behavioral intervention, pharmacotherapy, bariatric surgery
- **Learning objectives:** Comprehensive obesity care

---

## References and Guidelines

### Primary Guidelines
1. **American Diabetes Association Standards of Care (2024)**
2. **ACC/AHA Hypertension Guidelines (2023)**
3. **GOLD COPD Guidelines (2023)**
4. **KDIGO CKD Guidelines (2023)**

### Key Evidence Sources
- UKPDS trial (diabetes)
- SPRINT trial (hypertension)
- TORCH trial (COPD)
- DAPA-HF trial (heart failure)

### Quality Metrics
- HbA1c control rates
- Blood pressure control rates
- COPD exacerbation prevention
- CKD progression rates

---

*Note: All scenarios are fictional and created for educational purposes. Patient information has been de-identified and modified for demonstration.*